AR038143A1 - Agonistas del receptor 2 del factor liberador de la corticotropina - Google Patents
Agonistas del receptor 2 del factor liberador de la corticotropinaInfo
- Publication number
- AR038143A1 AR038143A1 ARP030100100A ARP030100100A AR038143A1 AR 038143 A1 AR038143 A1 AR 038143A1 AR P030100100 A ARP030100100 A AR P030100100A AR P030100100 A ARP030100100 A AR P030100100A AR 038143 A1 AR038143 A1 AR 038143A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- corticotropine
- liberating
- agonists
- crf2r
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 102100038019 Corticotropin-releasing factor receptor 2 Human genes 0.000 abstract 2
- 101150081899 Crhr2 gene Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Un péptido no nativo que comprende la secuencia: ZGPPISIDLPX12X13LLRKX18IEIEKQEKEKQQAX32X33NAX36X37X37LX39X40X41, en donde: X12 se selecciona de F, Y, L, I, y T; X13 se selecciona de Q, W, y Y; X18 se selecciona de V y M; X32 se selecciona de T y A; X33 se selecciona de N y T; X36 se selecciona de R y L; X37 se selecciona de L y I; X39 se selecciona de D y A; X40 se selecciona de T y R; X41 se selecciona de I y V; y variantes de éstos. Las correspondientes definiciones y secuencias de dichos sustituyentes se incluyen en la Memoria. Uso para preparar una composición farmacéutica útil para evitar o tratar un trastorno modulado por CRF2R que comprende una cantidad segura y eficaz de dicho péptido. Ácido nucleico aislado que codifica dicho péptido. Anticuerpo aislado específico para dicho péptido. Composición farmacéutica que comprende dicho péptido y un portador farmacéuticamente aceptable. Conjunto o Kit para evitar o tratar un trastorno modulado por CRF2R que comprende dicho péptido en forma de dosis unitaria e instrucciones de uso.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34911702P | 2002-01-16 | 2002-01-16 | |
| US37633702P | 2002-04-29 | 2002-04-29 | |
| US38889502P | 2002-06-14 | 2002-06-14 | |
| US41198802P | 2002-09-19 | 2002-09-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038143A1 true AR038143A1 (es) | 2004-12-29 |
Family
ID=27617822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100100A AR038143A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
| ARP030100101A AR038144A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
| ARP030100099A AR038142A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100101A AR038144A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
| ARP030100099A AR038142A1 (es) | 2002-01-16 | 2003-01-15 | Agonistas del receptor 2 del factor liberador de la corticotropina |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US6936585B2 (es) |
| EP (4) | EP1724283B1 (es) |
| JP (3) | JP4508648B2 (es) |
| KR (3) | KR100758858B1 (es) |
| CN (3) | CN100475844C (es) |
| AR (3) | AR038143A1 (es) |
| AT (4) | ATE362488T1 (es) |
| AU (2) | AU2003205197B2 (es) |
| BR (3) | BR0306878A (es) |
| CA (3) | CA2470743C (es) |
| CY (1) | CY1106133T1 (es) |
| DE (4) | DE60318547T2 (es) |
| DK (2) | DK1465923T3 (es) |
| ES (4) | ES2299701T3 (es) |
| IL (5) | IL162529A0 (es) |
| MA (3) | MA27592A1 (es) |
| MX (3) | MXPA04006883A (es) |
| MY (1) | MY140306A (es) |
| NO (3) | NO20043366L (es) |
| NZ (3) | NZ533600A (es) |
| PE (3) | PE20030849A1 (es) |
| PL (3) | PL373139A1 (es) |
| PT (2) | PT1465923E (es) |
| RU (1) | RU2294333C2 (es) |
| SA (3) | SA03230564A (es) |
| SI (1) | SI1465921T1 (es) |
| TW (3) | TW200302276A (es) |
| WO (3) | WO2003062268A2 (es) |
| ZA (1) | ZA200404995B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002024732A2 (en) * | 2000-09-22 | 2002-03-28 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften | Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
| WO2005103690A2 (en) * | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) |
| AU2006235045A1 (en) * | 2005-03-30 | 2006-10-19 | J. Craig Venter Institute, Inc. | Haemophilus influenzae type b |
| WO2007090087A2 (en) * | 2006-01-27 | 2007-08-09 | Research Development Foundation | Use of corticotropin releasing factor receptor-2 inhibitors for treating insulin-related diseases |
| WO2009033773A2 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent |
| AU2008297874A1 (en) * | 2007-09-11 | 2009-03-19 | Mondobiotech Laboratories Ag | Use of secretin and optionally urodilatin as therapeutic agents |
| WO2009046874A1 (en) * | 2007-09-11 | 2009-04-16 | Mondobiotech Laboratories Ag | Therapeutic combination of trh-potentiating peptide and stresscopin |
| ES2723098T3 (es) * | 2008-11-04 | 2019-08-21 | Janssen Pharmaceutica Nv | Agonistas del péptido CRHR2 y usos de los mismos |
| EP2206726A1 (en) * | 2009-01-08 | 2010-07-14 | Universite Joseph Fourier | Non-invasive tools for detecting vulnerable atherosclerotic plaques |
| CN102711801A (zh) * | 2009-11-04 | 2012-10-03 | 詹森药业有限公司 | 用顶压素样肽治疗心力衰竭的方法 |
| US9314506B2 (en) | 2011-10-24 | 2016-04-19 | Research Development Foundation | Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors |
| CN104220098B (zh) * | 2012-02-14 | 2018-04-10 | 加利福尼亚大学董事会 | 用于心血管疾病和其它病况的旁分泌基因的全身性递送和受调节的表达 |
| JOP20170153A1 (ar) * | 2016-07-15 | 2019-01-30 | Lilly Co Eli | نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة |
| EP3528622A4 (en) * | 2016-10-20 | 2020-08-05 | Cortene Inc. | METHODS OF TREATING ILLNESSES DUE TO IMPROPER STRESS RESPONSE |
| CN110755434B (zh) * | 2018-07-27 | 2022-03-15 | 中国医学科学院药物研究所 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
| WO2025184558A1 (en) * | 2024-02-28 | 2025-09-04 | Caradon Therapeutics, Inc. | Modified urocortin 3 |
| WO2025222010A1 (en) * | 2024-04-19 | 2025-10-23 | Neurocrine Biosciences, Inc. | Corticotropin releasing factor receptor 2 (crfr2) agonists |
| WO2025230248A1 (ko) * | 2024-04-30 | 2025-11-06 | 한미약품 주식회사 | Crf2 수용체 작용제와 그 아실화 결합체의 용도 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235036A (en) * | 1991-05-31 | 1993-08-10 | The Salk Institute For Biological Studies | Crf analogs |
| EP0860501A3 (en) | 1994-06-14 | 1999-05-19 | Neurocrine Biosciences, Inc. | Corticotropin-releasing factor2 receptors |
| US5786203A (en) * | 1994-06-14 | 1998-07-28 | Neurocrine Biosciences, Inc. | Isolated nucleic acid encoding corticotropin-releasing factor2 receptors |
| US5824771A (en) * | 1994-12-12 | 1998-10-20 | The Salk Institute For Biological Studies | Cyclic CRF agonists |
| US5663292A (en) * | 1994-12-12 | 1997-09-02 | The Salk Institute For Biological Studies | Cyclic CRF analogs |
| US5660824A (en) | 1995-05-24 | 1997-08-26 | Grabstein; Kenneth H. | Muscle trophic factor |
| AU6277796A (en) | 1995-06-13 | 1997-01-15 | Salk Institute For Biological Studies, The | Urocortin peptides |
| US5869450A (en) | 1996-03-06 | 1999-02-09 | The Regents Of The University Of California | Anti-inflammatory compositions and method with corticotropin-releasing factor analogs |
| US6838274B2 (en) | 2000-08-04 | 2005-01-04 | Research Development Foundation | Urocortin proteins and uses thereof |
| WO2002024732A2 (en) * | 2000-09-22 | 2002-03-28 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften | Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr) |
| US20020082409A1 (en) | 2000-10-26 | 2002-06-27 | Hsu Sheau Yu | Stresscopins and their uses |
| US6670140B2 (en) * | 2001-03-06 | 2003-12-30 | The Procter & Gamble Company | Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors |
| US6936585B2 (en) * | 2002-01-16 | 2005-08-30 | The Procter & Gamble Company | Corticotropin releasing factor 2 receptor agonists |
-
2002
- 2002-12-11 US US10/317,252 patent/US6936585B2/en not_active Expired - Lifetime
- 2002-12-11 US US10/315,964 patent/US7192923B2/en not_active Expired - Fee Related
- 2002-12-11 US US10/317,251 patent/US7192924B2/en not_active Expired - Fee Related
-
2003
- 2003-01-10 TW TW092100532A patent/TW200302276A/zh unknown
- 2003-01-10 TW TW092100533A patent/TWI300442B/zh not_active IP Right Cessation
- 2003-01-10 TW TW092100535A patent/TW200302278A/zh unknown
- 2003-01-14 PE PE2003000041A patent/PE20030849A1/es not_active Application Discontinuation
- 2003-01-14 PE PE2003000040A patent/PE20030974A1/es not_active Application Discontinuation
- 2003-01-14 PE PE2003000039A patent/PE20030747A1/es not_active Application Discontinuation
- 2003-01-15 MY MYPI20030136A patent/MY140306A/en unknown
- 2003-01-15 AR ARP030100100A patent/AR038143A1/es unknown
- 2003-01-15 AR ARP030100101A patent/AR038144A1/es unknown
- 2003-01-15 AR ARP030100099A patent/AR038142A1/es unknown
- 2003-01-16 PT PT03731965T patent/PT1465923E/pt unknown
- 2003-01-16 BR BR0306878-1A patent/BR0306878A/pt not_active IP Right Cessation
- 2003-01-16 JP JP2003562145A patent/JP4508648B2/ja not_active Expired - Fee Related
- 2003-01-16 PL PL03373139A patent/PL373139A1/xx not_active Application Discontinuation
- 2003-01-16 PT PT03703867T patent/PT1465921E/pt unknown
- 2003-01-16 WO PCT/US2003/001451 patent/WO2003062268A2/en not_active Ceased
- 2003-01-16 KR KR1020047011057A patent/KR100758858B1/ko not_active Expired - Fee Related
- 2003-01-16 ES ES03731963T patent/ES2299701T3/es not_active Expired - Lifetime
- 2003-01-16 MX MXPA04006883A patent/MXPA04006883A/es active IP Right Grant
- 2003-01-16 AT AT03731965T patent/ATE362488T1/de not_active IP Right Cessation
- 2003-01-16 JP JP2003562154A patent/JP4489434B2/ja not_active Expired - Fee Related
- 2003-01-16 EP EP06117810A patent/EP1724283B1/en not_active Expired - Lifetime
- 2003-01-16 EP EP03731965A patent/EP1465923B1/en not_active Expired - Lifetime
- 2003-01-16 IL IL15252903A patent/IL162529A0/xx unknown
- 2003-01-16 MX MXPA04006884A patent/MXPA04006884A/es active IP Right Grant
- 2003-01-16 NZ NZ533600A patent/NZ533600A/en unknown
- 2003-01-16 MX MXPA04006885A patent/MXPA04006885A/es active IP Right Grant
- 2003-01-16 ES ES03731965T patent/ES2287484T3/es not_active Expired - Lifetime
- 2003-01-16 CA CA2470743A patent/CA2470743C/en not_active Expired - Fee Related
- 2003-01-16 AT AT03703867T patent/ATE334147T1/de not_active IP Right Cessation
- 2003-01-16 KR KR1020047011052A patent/KR100758857B1/ko not_active Expired - Fee Related
- 2003-01-16 ES ES03703867T patent/ES2269976T3/es not_active Expired - Lifetime
- 2003-01-16 AU AU2003205197A patent/AU2003205197B2/en not_active Ceased
- 2003-01-16 RU RU2004124847/13A patent/RU2294333C2/ru active
- 2003-01-16 KR KR1020047011051A patent/KR100735586B1/ko not_active Expired - Fee Related
- 2003-01-16 JP JP2003562146A patent/JP4508649B2/ja not_active Expired - Fee Related
- 2003-01-16 AT AT06117810T patent/ATE398632T1/de not_active IP Right Cessation
- 2003-01-16 EP EP03731963A patent/EP1465922B1/en not_active Expired - Lifetime
- 2003-01-16 DE DE60318547T patent/DE60318547T2/de not_active Expired - Lifetime
- 2003-01-16 NZ NZ533599A patent/NZ533599A/en unknown
- 2003-01-16 BR BR0306826-9A patent/BR0306826A/pt not_active IP Right Cessation
- 2003-01-16 DE DE60307044T patent/DE60307044T2/de not_active Expired - Lifetime
- 2003-01-16 IL IL16253003A patent/IL162530A0/xx unknown
- 2003-01-16 NZ NZ533598A patent/NZ533598A/en unknown
- 2003-01-16 IL IL16243103A patent/IL162431A0/xx unknown
- 2003-01-16 CN CNB038023520A patent/CN100475844C/zh not_active Expired - Fee Related
- 2003-01-16 CN CNA038023709A patent/CN1617887A/zh active Pending
- 2003-01-16 EP EP03703867A patent/EP1465921B1/en not_active Expired - Lifetime
- 2003-01-16 DE DE60313845T patent/DE60313845T2/de not_active Expired - Lifetime
- 2003-01-16 BR BR0306838-2A patent/BR0306838A/pt not_active Application Discontinuation
- 2003-01-16 CA CA2470731A patent/CA2470731C/en not_active Expired - Fee Related
- 2003-01-16 DK DK03731965T patent/DK1465923T3/da active
- 2003-01-16 WO PCT/US2003/001461 patent/WO2003062269A2/en not_active Ceased
- 2003-01-16 PL PL03371364A patent/PL371364A1/xx unknown
- 2003-01-16 SI SI200330360T patent/SI1465921T1/sl unknown
- 2003-01-16 ES ES06117810T patent/ES2309909T3/es not_active Expired - Lifetime
- 2003-01-16 AT AT03731963T patent/ATE383372T1/de not_active IP Right Cessation
- 2003-01-16 WO PCT/US2003/001454 patent/WO2003062277A1/en not_active Ceased
- 2003-01-16 PL PL03373529A patent/PL373529A1/xx not_active Application Discontinuation
- 2003-01-16 DE DE60321730T patent/DE60321730D1/de not_active Expired - Lifetime
- 2003-01-16 AU AU2003237419A patent/AU2003237419B2/en not_active Ceased
- 2003-01-16 CN CNB038023644A patent/CN100391972C/zh not_active Expired - Fee Related
- 2003-01-16 CA CA2470656A patent/CA2470656C/en not_active Expired - Fee Related
- 2003-01-16 DK DK03703867T patent/DK1465921T3/da active
- 2003-03-01 SA SA03230564D patent/SA03230564A/ar unknown
- 2003-03-01 SA SA3230565A patent/SA03230565B1/ar unknown
- 2003-03-01 SA SA3230564A patent/SA03230564B1/ar unknown
-
2004
- 2004-06-24 ZA ZA2004/04995A patent/ZA200404995B/en unknown
- 2004-07-13 MA MA27780A patent/MA27592A1/fr unknown
- 2004-07-13 MA MA27778A patent/MA27590A1/fr unknown
- 2004-07-13 MA MA27779A patent/MA27591A1/fr unknown
- 2004-08-13 NO NO20043366A patent/NO20043366L/no not_active Application Discontinuation
- 2004-08-13 NO NO20043371A patent/NO20043371L/no not_active Application Discontinuation
- 2004-08-16 NO NO20043396A patent/NO20043396L/no not_active Application Discontinuation
-
2005
- 2005-05-04 US US11/121,612 patent/US7462597B2/en not_active Expired - Fee Related
-
2006
- 2006-07-28 CY CY20061101051T patent/CY1106133T1/el unknown
-
2007
- 2007-02-02 US US11/701,576 patent/US7608701B2/en not_active Expired - Fee Related
- 2007-02-02 US US11/701,912 patent/US7632933B2/en not_active Expired - Fee Related
-
2009
- 2009-01-07 IL IL196384A patent/IL196384A0/en unknown
- 2009-03-24 IL IL197774A patent/IL197774A0/en unknown
- 2009-10-26 US US12/605,718 patent/US7897731B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038143A1 (es) | Agonistas del receptor 2 del factor liberador de la corticotropina | |
| TR200201874T2 (tr) | Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler. | |
| EA200702093A1 (ru) | Антитела-миметики glp-1 человека, композиции, способы и их применение | |
| EA200501268A1 (ru) | Ингибирующие вич 1,2,4-триазины | |
| SE9800836D0 (sv) | New Compounds | |
| EA200201271A1 (ru) | Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1 | |
| EA200101005A1 (ru) | Высокоэффективные композиции, содержащие дигидроэрготамин | |
| TW200510375A (en) | New compounds | |
| EA200500406A1 (ru) | Активный ингибитор серинпротеазы hcv | |
| WO2003103603A3 (en) | Novel formate salt of o-desmethyl-venlafaxine | |
| NO20055863L (no) | W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer | |
| NO20051688L (no) | Farmasoytiske blandinger som har en modifisert baerer | |
| EP1248612A4 (en) | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | |
| ECSP055701A (es) | Nuevos derivados de pirimidinamida y el uso de los mismos | |
| NO20060416L (no) | Ny anvendelse I | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| ATE364595T1 (de) | Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika | |
| ATE499939T1 (de) | Neue pharmazeutische zusammenstezungen, flibanserin polymorph a enthaltend | |
| SE0302546D0 (sv) | New compounds | |
| AR049274A1 (es) | Acido2-{[2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil]amino}-3-(fenilpiridin-2-ilamino)propionico sustancialmente puro como inhibidor selectivo de la quinasa ikk-2 | |
| DK1781277T3 (da) | Kombinationssammensætning, der omfatter Ibuprofen og Paracetamol | |
| DE60121804D1 (de) | Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin | |
| NO20014855L (no) | N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister | |
| CL2003002588A1 (es) | Uso de una composicion farmaceutica que comprende acido n,n-dimetoximetildifenil barbiturico, acido n-metoximetildifenil barbiturico o acido difenil barbiturico o una sal farmaceuticamente aceptable del mismo para preparar un medicamento util en el t | |
| DE60134735D1 (de) | Neue neurokinin-antagonisten zum gebrauch als arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |